News
Heidi Shupe has a myriad of medals proudly displayed in her home. But 20 years ago, her life looked a lot different.
In January 2023, the Brukinsa, a next-generation BTK inhibitor, received FDA approval for chronic lymphocytic leukemia (CLL).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback